ArticleInternational journal of clinical oncology2025
Ischemic stroke in patients with unresectable pancreatic and gastric cancer.
Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Stroke secondary to cancer-associated coagulopathy: a systematic review.Journal of neurology · 2026Pooled it
- Association of red blood cells, D-dimer, and 13-(S)-HODE with cancer-related ischemic stroke: a case-control study.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundThromboembolism, including ischemic stroke and venous thromboembolism (VTE), is a critical complication in patients with advanced cancer. Pancreatic cancer and gastric cancer are classified as "very high risk" cancers based on the Khorana score, a risk model for VTE. However, the cumulative incidence of ischemic stroke in patients with unresectable pancreatic and gastric cancers has not been elucidated. This study evaluated the incidence and mortality of ischemic stroke in patients with unresectable pancreatic and gastric cancer.
methodsThis retrospective, single-center cohort study included patients diagnosed with unresectable pancreatic or gastric cancer between January 2009 and December 2021.
resultsAmong 276 patients, ischemic stroke occurred in 18 patients. All 18 patients were categorized into cancer-associated stroke (CAS), including cancer-related coagulopathy, by a board certified fellow. The 1-year cumulative incidence rates were 10.2% in patients with unresectable pancreatic cancer and 5.8% in patients with unresectable gastric cancer (P = 0.22). The median survival time after stroke was significantly shorter for patients with unresectable pancreatic cancer than for patients with unresectable gastric cancer (41 days vs 116 days, P < 0.05). In contrast, no significant difference was observed in overall survival (OS) between patients with and without ischemic stroke (244 days vs 221 days, P = 0.66).
conclusionThis study's findings indicated that CAS accounts for most ischemic stroke in patients with unresectable pancreatic and gastric cancers. Moreover, the prognosis after ischemic stroke was significantly worse in patients with unresectable pancreatic cancer. However, ischemic stroke itself may not influence OS in patients with unresectable pancreatic or gastric cancer.
Indexed as
Identifiers
40056275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.